The core objective of market access is to ensure that all appropriate patients who would benefit from a new product get rapid and maintained access to the new treatment, at the right price. This is done by demonstrating the clinical and economic value of an authorized product in order to obtain optimal reimbursement.
Payers (non-clinical budget holders) are now major decision makers in pharmaceutical reimbursement. Meeting a clinical trial endpoint and gaining a product license is not always a guarantee of success. National and regional healthcare budget holders can ask additional questions in areas such as: cost-effectiveness, comparative clinical effectiveness, competitive rationalization, and budget optimization. Unlimited healthcare budgets and cost containment strategies drive the need for a compelling market access strategy and value proposition in order to secure optimal reimbursement.
Our Strategic Market Access (SMA) team has the expertise to design relevant and impactful evidence-based strategies for optimal market access of your product. Our consultants are experts in developing pricing and reimbursement strategies, payer value propositions, value dossiers, Health Technology Assessment (HTA) submissions, evidence generation plans, value communication tools, and conducting strategic and systematic literature reviews. We engage with payers to validate our proposed strategies and value propositions to ensure that they resonate with reimbursement agencies and budget holders at all levels of global health systems.